A cancer drug that costs a retailer ₹2,700 is being sold to patients for ₹27,000. That tenfold gap — confirmed by the Supreme Court of India itself, drawing on figures placed before the bench — is what prompted Justices Vikram Nath and Sandeep Mehta to use a word rarely heard in a courtroom: “carnage.” The remark, made on September 30, 2026, wasn’t an isolated outburst. It was the latest escalation in a case the same bench had, just a week earlier on September 22, already described as “broad daylight dacoity” — and together, these two hearings have triggered what may become the most consequential pricing intervention in India’s private hospital sector in years.
What the Supreme Court Actually Said, and When
The timeline matters here, because the Court’s language has been escalating hearing by hearing, not staying static. On September 22, 2026, the bench expressed shock at the overpricing of essential cancer medicines, specifically citing a drug supplied to retailers for ₹2,700 carrying an MRP of ₹27,000 — and calling the practice “broad daylight dacoity” against patients. The judges pointedly asked how patients could be “cheated like this,” and voiced frustration that the regulatory authorities responsible for oversight had stayed silent: “It is very surprising that the authorities who are supposed to take action on this are silent.”
A week later, on September 30, the Court returned to the issue with even sharper language. Citing a comparable example — a cancer medicine supplied to retailers for ₹3,520 but sold to patients for ₹22,427 — the bench said plainly: “This is carnage.” Justice Mehta went further, describing how corporate hospitals operate: “Corporate hospitals don’t spare anyone. They won’t allow even the dead body to be taken out. The pharma sector is not bothered.” The Court’s frustration extended to who ultimately absorbs the cost of this system — noting that, where insurance or public schemes are involved, “the loser is the honest taxpayer.”
Crucially, the September 30 hearing moved from outrage to a concrete regulatory proposal: the Court asked why a uniform 16% margin — the difference between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) — shouldn’t apply across all medicines, rather than the current system under which some drug categories carry dramatically higher permitted markups than others.
The Legal Mechanism Behind the Markup
To understand why the Court is focused on this specific 16% figure, it helps to understand the regulatory structure the case is actually probing. Under India’s Drugs (Prices Control) Order (DPCO), medicines are divided into scheduled and non-scheduled categories. Scheduled medicines — those on the government’s National List of Essential Medicines — have their prices directly capped by the National Pharmaceutical Pricing Authority (NPPA). Non-scheduled medicines, by contrast, are subject to a much lighter-touch rule: manufacturers can raise prices by no more than roughly 10% annually, but there is no equivalent cap on the margin a distributor or retailer can add on top of the manufacturing price before it reaches the patient.
That gap — tight control over price increases, but comparatively loose control over markup margins — is precisely where a ₹2,700 drug can legally reach a ₹27,000 shelf price. The Court’s proposed fix, a flat 16% PTR-to-MRP margin applied uniformly across both scheduled and non-scheduled medicines, would directly close that structural loophole by removing the distinction the current system draws between essential and non-essential drug categories when it comes to markup permissibility.
Why Cancer Patients Specifically Are at the Center of This Case
Cancer treatment sits at a uniquely painful intersection of medical necessity and financial exposure, which is almost certainly why the petitions driving this case centered on oncology drugs rather than medicines generally. Cancer treatment is typically long-term, high-cost, and non-negotiable — patients cannot simply delay chemotherapy or targeted therapy the way they might defer an elective procedure, which removes much of the price sensitivity and comparison-shopping that normally functions as a check on markups in other parts of the healthcare market.
The Court specifically flagged a second, compounding practice: corporate hospitals frequently require patients to purchase medicines exclusively through in-house or hospital-designated pharmacies, rather than allowing patients to source the same drug from any licensed pharmacy at a potentially lower price. Justice Mehta’s exchange with Solicitor General Tushar Mehta, representing the Centre, captured exactly why this restriction matters: he noted that if a hospital pharmacist offered to sell a drug to a needy patient at the lower ₹2,700 retailer price instead of the marked-up MRP, the patient might actually become suspicious the medicine was spurious or counterfeit — a telling illustration of how deeply the inflated price has become normalized as the expected, “legitimate-seeming” cost, even though it represents the markup itself.
One petition before the Court specifically seeks a direction requiring authorities to make drug formulations more cost-effective by preventing unethical overpricing of essential medicines by manufacturers and retailers alike — framing this not as an isolated hospital-billing dispute, but as a structural failure spanning the full distribution chain from manufacturer to patient bedside.
The Market’s Immediate Reaction
The financial markets treated the Court’s intervention as a genuine, material threat to hospital sector economics — not just rhetorical pressure. Indian hospital stocks erased roughly ₹248 billion (about $2.6 billion) in combined market value in the trading session following the Court’s remarks. Apollo Hospitals Enterprise slumped 5.7%, Fortis Healthcare dropped 6.3%, and Max Healthcare Institute fell 5.3% — a sharp, sector-wide reaction reflecting investor concern that high-margin, in-house pharmacy revenue, long an important profit contributor for corporate hospital chains, could face direct regulatory constraint.
That reaction is itself informative about how central drug sales have become to private hospital profitability. A uniform 16% margin cap, if actually implemented, would meaningfully compress one of the more lucrative revenue lines within the broader hospital business model — explaining why the market moved so quickly and sharply on what is, procedurally, still an ongoing case rather than a finalized ruling.
What Happens Next
The Supreme Court has scheduled the next hearing for October 12, 2026, and has specifically asked the Central Government to respond on why a uniform 16% margin rule shouldn’t be applied across all medicine categories. The Court has indicated the matter will also examine the broader distinction between scheduled and non-scheduled medicines under the DPCO framework, along with the ethics of medical practitioners in their dealings with patients regarding drug sales and prescribing practices tied to hospital pharmacies.
This isn’t the first time India’s courts have intervened directly in pharmaceutical pricing and access in ways that reshaped the market — a separate, unrelated Kerala High Court matter has recently asked the Centre to assess the affordability of the cancer drug Ribociclib before a patent-related decision, reflecting a broader judicial pattern of scrutinizing cancer-drug pricing and access from multiple angles simultaneously, not just through this one Supreme Court case.
What a Uniform 16% Margin Would Actually Mean for Patients
If the Court’s proposed uniform margin is eventually adopted — whether through judicial direction or a government policy response to the Court’s prompting — the practical effect for cancer patients and their families would be direct and significant. A drug currently marked up tenfold, from ₹2,700 to ₹27,000, would under a strict 16% PTR-to-MRP rule instead sell for roughly ₹3,132 — an approximately 88% reduction in what the patient actually pays at the pharmacy counter, assuming the rule is applied and enforced as described.
Beyond the margin cap itself, the Court’s scrutiny of mandatory in-house pharmacy requirements at corporate hospitals addresses a second, independent source of patient cost: even a correctly regulated margin doesn’t help a patient who has no choice but to purchase from a single, hospital-controlled pharmacy. Addressing both issues together — the margin itself, and the restriction on where patients can purchase — is what gives this case the potential to meaningfully change out-of-pocket cancer treatment costs, rather than closing one loophole while leaving a parallel one open.
The Bigger Picture
The Supreme Court’s escalating language — from “broad daylight dacoity” on September 22 to “carnage” on September 30 — reflects a judiciary that has moved well past procedural caution into open, direct condemnation of a pricing practice it views as exploiting patients at their most vulnerable and financially exposed moment. For cancer patients and their families, who often face treatment costs extending over months or years, a markup this size compounds directly into financial devastation; the Court itself has previously noted elsewhere that patients are frequently compelled to sell jewellery to afford treatment under the current pricing structure.
Whether this results in a formal, enforceable 16% margin cap, continued government deliberation, or some intermediate regulatory compromise will become clearer at the October 12 hearing — but the market’s immediate, sharp reaction, and the Court’s own hardening language across just two hearings, suggest this is no longer a routine public interest litigation quietly working through the system. It has become a live, high-stakes regulatory confrontation with the potential to directly reshape how much Indian cancer patients pay for the medicines keeping them alive.
